Movement Alert|Revolution Medicines, Inc. Pre-Market Rise 4.1%, EU Approves Rasonque for Metastatic Pancreatic Cancer

Market Focus
11/20

On November 20, Revolution Medicines, Inc. rose 4.1% in Pre-Market Trading, with the stock trading at $164.0 and turnover of $53.26 thousand.

The clearest catalyst is the company’s recently disclosed European Commission approval of Rasonque monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, with or without an identified RAS tumor mutation.

The authorization covers European Union member states and the European Economic Area, though not the UK or Switzerland. The approval was supported by a phase 3 trial that met all primary and key secondary endpoints, extending the drug’s commercial reach beyond the US. Supporting sentiment has also remained constructive, with RBC earlier raising its price target to $321 and maintaining an Outperform rating after the company’s latest quarterly update.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10